Journal ArticleDOI
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study
Dean F. Bajorin,M F Sarosdy,David G. Pfister,M Mazumdar,Robert J. Motzer,Howard I. Scher,Nancy L. Geller,William R. Fair,H Herr,Pramod C. Sogani +9 more
Reads0
Chats0
TLDR
Cisplatin remains as the standard platinum analog in the treatment of patients with good-risk GCTs and two-drug therapy with EC using this dose and schedule was inferior to therapy with EP.Abstract:
PURPOSEThis multicenter, randomized phase III clinical trial evaluated the efficacy of etoposide plus carboplatin (EC) versus etoposide plus cisplatin (EP) in good-risk germ cell tumor (GCT) patients.PATIENTS AND METHODSBetween October 1986 and December 1990, 270 patients with good-risk GCTs were randomized to receive four cycles of either EP or EC. The etoposide dose in all patients was 100 mg/m2 on days 1 through 5. EP patients received cisplatin at 20 mg/m2 on days 1 through 5 and therapy was recycled at 21-day intervals. For EC patients, the carboplatin dose was 500 mg/m2 on day 1 of each cycle and the EC recycling interval was 28 days.RESULTSTwo hundred sixty-five patients were assessable: 131 patients treated with EC and 134 treated with EP. One hundred fifteen of 131 assessable patients (88%) treated with EC achieved a complete response (CR) versus 121 of 134 patients (90%) treated with EP (P = .32). Sixteen patients (12%) treated with EC relapsed from CR versus four patients (3%) treated with EP. ...read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Testicular Germ-Cell Cancer
George J. Bosl,Robert J. Motzer +1 more
TL;DR: This review discusses recent developments in understanding germ-cell tumors, a term that indicates their origin in primordial germ cells, and management, which has changed substantially in the past 20 years because of the ability of cisplatin-containing combination chemotherapy to cure advanced disease.
Journal ArticleDOI
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Ronald S. Go,Alex A. Adjei +1 more
TL;DR: Carboplatin does not possess equivalent activity to cisplatin in all platinum-sensitive tumors, and its role in limited-stage small-cell lung cancer needs to be investigated further.
Journal ArticleDOI
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions.
Rossella Marullo,Erica Werner,Natalya Degtyareva,Bryn S. Moore,Giuseppe Altavilla,Suresh S. Ramalingam,Paul W. Doetsch +6 more
TL;DR: Exposure to cisplatin induces a mitochondrial-dependent ROS response that significantly enhances the cytotoxic effect caused by nDNA damage and may lead to the design of novel therapeutic strategies to improve anticancer drug efficacy.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A multiple testing procedure for clinical trials.
TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Journal ArticleDOI
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Ah Calvert,David Richard Newell,L A Gumbrell,S O'Reilly,M Burnell,F. E. Boxall,Zahid H Siddik,Ian Judson,Martin Gore,E Wiltshaw +9 more
TL;DR: The formula provides a simple and consistent method of determining carboplatin dose in adults and will not be influenced by previous or concurrent myelosuppressive therapy or supportive measures, and is applicable to combination and high-dose studies as well as conventional single-agent therapy, although the target AUC will need to be redefined for combination chemotherapy.
Journal ArticleDOI
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide
Stephen D. Williams,Stephen D. Williams,R. Birch,R. Birch,Lawrence H. Einhorn,Irwin L,Irwin L,F A Greco,F A Greco,Patrick J. Loehrer +9 more
TL;DR: It is concluded that etoposide with cisplatin and bleomycin is superior to vinblastine with cisPlatin and Bleomycin in the treatment of disseminated germ-cell tumors because of diminished neuromuscular toxicity and, among patients with advanced disease, better efficacy.
Related Papers (5)
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
Graham M. Mead,S. P. Stenning,P. A. Cook,Sophie D. Fosså,Alan Horwich,Stan B. Kaye,R.T.D. Oliver,Phm deMulder,R deWit,Gerrit Stoter,Richard Sylvester,Dean F. Bajorin,George J. Bosl,M Mazumdar,Craig R. Nichols,Robert J. Amato,Giorgio Pizzocaro,Jean-Pierre Droz,Andrew Kramar,Gedske Daugaard,H. Cortes-Funes,Luis Paz-Ares,John A. Levi,B. M. Colls,V J Harvey,C Coppin +25 more